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Intracellular calcium concentration and activation of the Na/W
exchanger in essential hypertension. To investigate the relationship
between changes in intracellular calcium concentration ([Ca211,) and
agonist-induced activation of the Na/H exchanger in essential hyper-
tension (EH), platelet [Ca2]1 and pH1 were measured in 24 patients with
EH (14 males) aged 48 2 years and 23 matched normotensive controls
(NT) (12 males) aged 45 3 years. Measurements were done with
spectrofluorimetry using the dyes Fura-2 for [Ca2]1 and BCECF for
pH1. [Ca2]1 and pH1 were measured in the resting condition and after
stimulation in vitro with 0.1 U/mI human thrombin. The thrombin-
induced rise in pH1 was Na dependent and amiloride sensitive,
indicating that it was mediated by the Na/H exchanger. Unstimulated
[Ca24]1 was higher in patients with EH than in NT (60 3 vs. 48 I
nmol/liter, P < 0.005), but there were no differences in resting pH,
between both groups (7.16 0.01 vs. 7.16 0.008). In the presence of
1 mmol/liter external calcium (Ca240), throinbin-induced increment in
[Ca24]1 was significantly greater in patients with EH than in NT (281
21 vs. 206 19; P <0.05) as was the pH, increment(EH: 0.137 0.01;
NT: 0.095 0.01; P < 0.05). Both agonist-induced increments in
[Ca2'11 and in pH, were correlated with mean arterial pressure (MAP)
only in the EH group (r = 0.58, P < 0.005 and r = 0.59, P < 0.005,
respectively). The agonist-induced rise in pH, was positively correlated
with the rise in [Ca2i both in the EH group (r = 0.65, P < 0.001) and
in the NT (r = 0.55, P <0.01). At higher doses of thrombin (2.5 U/ml),
the enhanced increment in both platelet [Ca24] (EH: 732 20; NT: 619
15 nmol/liter, P < 0.05, N = 6) and in pH, (EH: 0.193 0.001; NT:
0.150 0.004 P < 0.005,N 6) was also observed in patients with EH.
In the absence of Ca20 (chelated with EGTA), there were no significant
differences between patients with EH and NT in thrombin-induced
increases neither in [Ca24] (EH: 140 18; NT: 121 22 nmolfliter) nor
in pH1 (EH: 0.098 0.01; NT: 0.079 0.01). When the agonist-induced
increase in [Ca2]1 was prevented with the Ca241 chelator MAPTAM, no
rise in pH, was observed in either group. In conclusion, in platelets
challenged with thrombin, the agonist-induced activation of the
Na4/H4 exchanger occurs in correlation with the increment in [Ca2],
and both are significantly increased in patients with EH only in the
presence of Ca20. Furthermore, the magnitude of the agonist-induced
changes in [Ca2]1 and in pH, showed a direct relationship with MAP in
the EH group. The agonist-induced activation of the Na4/H4 exchanger
requires a rise in [Ca24]1 both in patients with EH and in NT subjects.
A variety of cellular abnormalities in intracellular calcium
concentration ([Ca2],) regulation have been described in a
number of cell types in essential hypertension (EH) [1, 2].
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Elevated concentration of [Ca24], has been reported in platelets
from subjects with EH both in the resting state [3—51 and after
stimulation with thrombin [6]. Platelets have been used for
analysis of intracellular calcium metabolism in EH because of
the similarity of the calcium-dependent contractile processes
between these cells and vascular smooth muscle cells (VSMC)
[7]. In this regard, both cell types are activated by a rise in
[Ca24]1 which is manifested by smooth muscle cell contraction
and platelet aggregation. Therefore, platelet elevated [Ca24]1 in
EH may reflect increased VSMC reactivity which would be
expressed as increased vascular resistance and elevated blood
pressure.
Recently, it has been demonstrated that intracellular pH
(pH1) plays an important role as an intracellular signal for
extracellular hormonal messages [8, 9]. In this regard, the
changes in pH1 have been found to produce marked effects on
contraction in smooth muscle [9, 10]. Abnormalities in resting
pH1 have been described in circulating cells from essential
hypertensives as compared to normotensives with variable
results: increase [11, 12], no difference [13, 14] or decrease in
pH1 [15]. It is known that pH1 is regulated in part by the
membrane Na4/H exchanger which exchanges intracellular
H4 for extracellular Na [8—10, 16]. The Na4/H exchanger is
known to be responsive to vasoconstrictors, growth factors,
intracellular acidification and cell shrinking [8—10, 16, 171. More
consistently, Na/H4 exchanger activity in response to intra-
cellular acidification has been reported to be elevated in EH [11,
14, 18—20]. The importance of the Na/H exchanger activity in
EH is suggested by: (1) the broad number of contractile
functions potentially regulated by pH1 [10]; (2) its critical
involvement in cell growth and proliferation [16], which may
explain the abnormal hypertrophy and proliferation of VSMC
from hypertensive patients and spontaneously hypertensive
rats (SHR) with respect to controls; and (3) its importance as a
source of Na reabsorption in the epithelium of the renal
proximal tubules [21].
The changes observed in [Ca24]1 and pH1 in patients with EH
suggest that there may be a mutual control of these parameters
which could be important in the pathophysiology of EH.
However, there is controversy with respect to the interrelation-
ship between agonist-induced rise in [Ca24], and activation of
the Na4/H4 exchanger [16]. The purpose of this study was to
evaluate the relationship between agonist-induced rise in plate-
let [Ca2]1 and activation of the Na4/H exchanger in EH in an
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Table 1. Clinical and biochemical characteristics of the subjects
studied
Hypertensives Normotensives
Number (males) 24 (14) 23 (12)
Age years 48 2 45 3
Systolic BP mm Hg 173 4° 109 2
Diastolic BP 108 1° 71 1
Mean BP 129 i° 83 1
BMI kg/rn2 27 07b 25 0.6
PRA ng/rnl hr 0,43 0.08 0.34 0.05
NE pg/mi 274 21 263 28
Abbreviations are: BP, blood pressure; BMI, body mass index; PRA,
plasma renin activity; NE, norepinephrine. Values are means SEM.
ap< 0,01
b P < 0.05
attempt to further our knowledge about the role of [Ca2]1 in the
agonist-mediated activation of the Na/H exchanger.
Methods
Materials
Human thrombin from Sigma (St. Louis, Missouri, USA) was
resuspended in distilled water and stored at —20°C until use.
Fura-2-acetoxymethylester (Fura-2-AM), 2' ,7'-bis (carboxy-
ethyl)-5,6-carboxyfluorescein tetraacetoxymethylester (BCECF-
AM) and MAPTAM (1 ,2-bis-5-methyl-amino-phenoxylethane-
N,N,N'-tetra-acetoxymethyl acetate) were from Calbiochem
(La Jolla, California, USA), prepared in dimethyl sulfoxide
(DMSO) and stored at —20°C until use. EIPA [3-amino-5-
ethylisopropilamino-6-chloro-N-(diaminoethylene) pyrazine-
carboxamine hydrochloride] was provided by Merck Sharp &
Dohme, Spain. Nigericin, EGTA, digitonin, choline chloride
and N-methyl-D-glucamine were from Sigma. All other chemi-
cals were of analysis grade purchased from Merck (Darmstadt,
Germany).
Patients
Twenty-four Caucasian patients with EH and twenty-three
Caucasian normotensive subjects were included in the study
after informed consent. Subject clinical and biochemical char-
acteristics are shown in Table 1. None of the normotensive
control subjects had a family history of hypertension. Patients
were free of antihypertensive medication for at least three
weeks prior to the study, and none of the subjects were
receiving medications known to affect platelet function at least
10 days prior to the study. Subjects were excluded for the
following: secondary causes of hypertension, diabetes mellitus,
abnormal renal function, congestive heart failure, alcoholism
and women on birth control pills. Subjects were studied in the
fasting state between 8:00 and 10:00 a.m. An indwelling cannula
was inserted in an antecubital vein, and after a 60-minute supine
rest blood pressure was recorded with a conventional sphyg-
momanometer. The actual blood pressure used was the average
of three determinations separated five minutes. Fifty ml of
venous blood were sampled without stasis for measurement of
[Ca2]1 and pH1. Mean arterial blood pressure was calculated as
the diastolic pressure plus one third the pulse pressure. Body
mass index (BMI) was calculated as weight (kg)/height (rn)2.
Biochemical determinations
Preparation of cells. Fifty ml of venous blood was drawn into
20% (vol:vol) acid-citrate-glucose (2.5 g sodium citrate, 1.5 g
citric acid, 2.0 g glucose in 100 ml distilled water) and was
immediately centrifuged at 200 x g for 10 minutes at 20°C to
obtain the platelet-rich plasma (PRP). EGTA 0.5 mmollliter was
added to prevent platelet activation and the PRP was centri-
fuged at 500 X g for 20 minutes at 20°C. The pellet was
resuspended in HEPES-buffered saline (HBS) consisting of (in
mmollliter) NaC1 145, KC1 5, MgCl2 1, glucose 6, HEPES 10
and bovine serum albumin (BSA) 0.2 mg/mI, pH 7.4 at 37°C.
The platelet suspension was incubated either with 2 mo1Jliter
Fura-2-AM or 0.75 mol/liter BCECF-AM for 35 minutes at
37°C in a shaking water bath protected from light. The labeled
platelets were passed through a 2.5 x 10 cm Sepharose CL2B
column (Pharmacia, Uppsala, Sweden) preequilibrated with
HBS to remove the extracellular dye. Platelet count was
adjusted to 0.5 x l08/mi using a Technikon H-i System coulter
counter (Technikon Instruments Corp., Tarrytown, New York,
USA). CaCl2 to 1 mmollliter was added to replenish intracellu-
lar calcium stores. After an equilibration time of 15 minutes at
37°C, 2 ml of the platelet suspension were placed in a 3 ml
quartz cuvette for fluorescence measurements.
Fluorescence measurements
Fluorescence measurements were carried out in a Hitachi
F-2000 spectrofluorometer (Hitachi, Ltd. Tokyo, Japan). The
sample was contained in a 3 ml quartz cuvette placed in a
cuvette chamber thermostated at 37°C. During the individual
fluorescence readings the platelet suspension was continually
stirred with a magnetic stirrer at low speed to prevent platelet
activation. All additions were made directly into the cuvette
through a small hole in the top of the cuvette chamber with
microsample syringes. The fluorescence signal was obtained
once every second with alternate excitation wavelengths at 340
and 380 nm for Fura-2 and 500 and 440 nm for BCECF. [Ca2]1
and pH1 were estimated by the ratio of the excitation wave-
lengths 340/380 and 500/440, respectively. The emission wave-
length was 510 nm for Fura-2 and 530 nm for BCECF. Auto-
fluorescence of the unlabeled cell suspension with the vehicle
DMSO was recorded before and after lysis with digitonin and
subtracted from the total fluorescence, and was always <15%
and <6% of the fluorescence signal for Fura-2 and BCECF
readings, respectively.
Calculation of [Ca2 f]1 The relationship between fluores-
cence ratio at 340/380 and [Ca2]1 was obtained using the
equation
[Ca2]1 = Kd (R — Rmin)/(Rmax — R) x Fmjn!Fmax
[22], where Rmax is the ratio of fluorescence at saturating Ca2,
Rmtn is the ratio at zero Ca2, Fmjn and Fmax are the fluores-
cences at 380 nm in zero Ca2 and in saturating Ca2, respec-
tively. Kd is the effective dissociation constant of Fura-2 in
appropriate conditions and was taken to be 224 nmol/liter,
according to Grynkiewicz, Poenie and Tsien [22]. Calibration
was performed by the following procedure: after each single
experiment, cells were lysed with digitonin 50 p,mol/liter in the
presence of 1 mmollliter CaCl2 to obtain Rmax and Fmax.
Thereafter, to obtain Rmjn and Fmjn, EGTA 6 mmol/liter was
0C
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added and the pH of the cuvette was adjusted to 8.3 with 20
mmollliter Tris base.
[Ca2j, was measured under resting conditions, that is, with
unstimulated platelets and after stimulation with 0.1 U/ml
thrombin. The increment of [Ca2] in nmol/liter ([Ca2]1) was
calculated by subtracting baseline [Ca2]1 from the maximal
response to thrombin (Fig. 1).
Calculation of pH,. The fluorescence signal of BCECF was
calibrated to pH at the end of every single experiment. Platelets
were lysed with digitonin 50 smollliter and the fluorescence
signal was recorded at known values of pH from 6.5 to 8
simultaneously monitored by a combined microelectrode
(Hamilton, Bonaduz AG, Switzerland) inserted directly in the
cuvette. The pH, estimated from this calibration was corrected
for the shift in the excitation maximum of intracellular and
extracellular BCECF according to the method of Thomas et al
[23]. Platelets were resuspended in high K HEPES buffer
which contained in mmollliter: KC1 120, NaCl 20, glucose 6,
MgCl2 1, HEPES 10 (pH 6 at 37°C) and nigericin 2 g/ml
allowing the external pH to equal pH1. The external pH was
increased stepwise from 6 to 8 and the fluorescence signal was
recorded. The cells were then lysed with digitonin and the pH
decreased stepwise back to pH 6. The difference between the
intracellular and the postlysis calibrations curves showed that
the signal in the latter underestimated pH, by 0.13 0.02 pH
units (mean SEM; N = 21). The values presented in this work
have been corrected according to these data.
where pH1, is pH1 at a given time t, pH,0 is pH1 at the new
steady state, pH10 is pH1 at the initial time t = 0 (at the
beginning of pH, recovery), and k is the rate constant. This
equation was also assumed for the earliest part of the curve,
when recording was disturbed by mixing artifacts [25]. The
apparent initial rate of pH1 recovery was calculated as the
derivative at the initial point. The relation between initial pH1
and the initial rate of pH1 recovery was fitted to a sigmoidal
model [26], and the maximal initial velocity (Vmax) was com-
puted as the top plateau of the curve. The pH1 value for half
maximal activation of the exchanger (pH105) was also obtained.
To examine the kinetics of sodium activation of the Na/H
exchanger, the initial rate of pH1 recovery was evaluated at
different extracellular sodium concentrations (10, 40, 70, 100
and 140 mmol/liter) at a pH10 of 6.4. The relation between
extracellular sodium and the initial rate of pH1 recovery was
fitted to a sigmoidal model to obtain the Km for external
sodium. All mathematical calculations were obtained using the
computer program GraphPAD-INPLOT4 (GraphPAD Soft-
ware, San Diego, California, USA).
Intracellular Ca2 (Ca2,) clamp
Five minutes after addition of BCECF, 40 mo1Jliter of the
intracellular calcium chelator MAPTAM were added to the
loading medium and incubated for 30 minutes at 37°C. After-
wards, cells were washed as described above. Before addition
1000
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Intracellular pH was measured under resting conditions and
after stimulation with 0.1 U/ml of human thrombin. The incre-
ment of pH, in pH units was calculated by subtracting the
baseline pH, from the response at 300 seconds after stimulation
with thrombin (Fig. 1).
Manipulation of the Na/H exchanger
(1
2000
1000
(a)
As indicated above, experiments were performed in a nomi-
nally free bicarbonate buffer to assess the role of the Na/H
exchanger. Two methods were employed for inhibition of the
Na/H exchanger. First, the sodium of the HBS was iso-
B BCECF osmotically replaced by choline chloride. Secondly, the
amiloride-derivative specific exchanger-blocker, EIPA 50
/.LmoL/liter, was used [24]. Understanding the kinetics of the
Na/H exchanger under our experimental conditions, the
activity of the exchanger was measured by acidifying BCECF-
loaded platelets (1 jsmollliter) with nigericin 0.5 g/ml in sodium
free HBS without BSA (Na replaced isosmotically by N-meth-
yl-D-glucamine) of different pH values (at least 7 values ranging
from 6 to 7.2) essentially as described by Gardner et al [25].
After 10 minutes with nigericin the Na/H exchanger was
activated by adding 100 ,td aliquots of the pre-acidified platelets
(2 x l08/ml) to the cuvette containing 2 ml of sodium-HBS plus
0 BSA (pH 7.4 at 37°C). The dilution of the nigericin plus the BSA
0 100 200 300 400 500 eliminated any further effect of the ionophore and allowed the
pH1 recovery. This recovery was completely inhibited by 50
smolIliter EIPA, indicating that it was mediated by the Na/H
exchanger. The rate constants of every single pH1-dependent
recovery curve from acidification were obtained through non-
linear regression analysis of the data following the equation:
Time, seconds
Fig. 1. Representative traces of(A) Fura-2 fluorescence at 340 nm and
(B) BCECF fluorescence at 500 nm before and after stimulation with 0.1
U/mi human thrombin (arrow) of platelets of a hypertensive patient (a)
and a normotensive control (b).
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Table 2. [Ca2J1 and pH1 measurements in hypertensives and
normotensives
Hypertensives Normotensives
[Ca2]1 nmol/liter 60 3 48 1
pH, (pH units) 7.16 0.01 7.16 0.008
[Ca2]1 Ca0
pH1 Ca0
281
0.137 0.0l'
206 19
0.095 0.01
[Ca2J1 EGTA 140 18 121 22
pH EGTA 0.098 0.01 0.079 0.01
pH1 MAPTAM 6.95 0.02 6.90 0.02
pH1 MAPTAM —0.06 0.008 —0,05 0.008
The thrombin-induced increases in [Ca2]1 ([Ca2i1; nmollliter) and
pH1 (pH; pH units) were calculated by subtracting the baseline from
the maximal response and from the response at 300 seconds, respec-
tively. Abbreviations are: Ca0, presence of external calcium 1 mmol/
liter; EGTA, blockade of external calcium entry to the cell with EGTA
1.2 mmol/liter; MAPTAM, blockade of [Ca2]1 increase with the
intracellular calcium chelator MAPTAM 40 mol/liter. Values are
means SEM.
aP < 0.005
b P < 0.05
of the agonist, EGTA 1.2 mmol/liter was added to the platelet
suspension.
Statistical analysis
Data are presented as mean standard error of the mean
(sEM). Statistical comparisons were determined by Student's
test for unpaired data. Correlation coefficients were calculated
by the least squares method. Results were similar using non-
parametric tests. A value of P < 0.05 was considered statisti-
cally significant.
Results
Clinical and biochemical characteristics of the subjects are
summarized in Table 1. There were no differences with respect
to age, sex and the hormonal profile between both groups.
Under unstimulated conditions, platelet [Ca2]1 was signifi-
cantly higher in patients with EH than in NT (60 3 vs. 48
1 nmollliter, P < 0.005; Table 2). However, there were no
differences in basal pH1 between both groups (EH: 7.16 0.01,
NT: 7.16 0.008 pH units). The agonist-induced rise in [Ca2],
and the activation of the Na'iH' exchanger was evaluated by
stimulation of the platelets with 0.1 U/mI of thrombin in the
presence of 1 mmollliter external calcium (Ca20), in the
absence of Ca20, and with the intracellular calcium chelator
MAPTAM. In the presence of 1 mmol/liter Ca20, thrombin-
induced rise in [Ca2], was significantly greater in patients with
EH than in the NT controls (281 21 vs. 206 19, P < 0.05;
Table 2; Fig. 2). Under these circumstances, thrombin-induced
rise in pH1 was also significantly greater in the EH patients
(0.137 0.01 vs. 0.095 0.01, P < 0.05) as compared to the
NT. The increment in pH, reflects activation of the Na'iH
exchanger as it was abolished when platelets were pretreated
with EIPA 50 moIJliter, a specific inhibitor of the exchanger,
or resuspended in HBS in which sodium was isosmotically
substituted by choline chloride (data not shown). To know
about the kinetic parameters of the Na/H exchanger under
our experimental conditions, we evaluated in a group of pa-
tients and controls (N = 6) the maximal initial velocity Wmax)
(EH: 0.195 0.005, NT: 0.123 0.001 dpH1/30 s, P = 0.078),
*
U
I I
Ca20 1 m EGTA 1.2 m MAPTAM 40 .LM
Fig. 2. Thrombin-induced increments in [Ca'], (nmol/liter) (A) and in
pH1 (pH units) (B) in hypertensives () and normotensives (U): (1) in
the presence of 1 mmol/liter external calcium (Ca',); (2) in the absence
of extracellular calcium, chelated with EGTA 1.2 mmol/liter prior to the
addition of thrombin; and (3) in cells loaded with the intracellular
calcium chelator MAPTAM 40 pjnol/liter). Bars represent means
SEM, * P < 0.05.
pH105 (EH: 6.60 0.03, NT: 6.65 0.007, P = NS)and the Km
for extracellular sodium (EH: 63.23, NT: 60.6 2, P = NS).
At higher doses of thrombin (2.5 U/ml), the enhanced incre-
ment in both platelet [Ca2} (EH: 732 20; NT: 619 15
nmollliter, P <0.05, N = 6)and in pH1 (EH: 0.193 0.001; NT:
0.150 0.004; P < 0.005, N = 6) was also observed in patients
with EH. Both the thrombin-induced increases in [Ca2]1 and in
pH1 were positively correlated with MAP in the EH group (for
[Ca2i r = 0.58, P < 0.005; for pH1 r = 0.59; P < 0.005; Fig. 3).
It is important to note that the thrombin-induced rise in pH1 was
positively correlated with the increment in [Ca2i in both the
EH group (r = 0.65;P < 0.001) and in the NT controls (r 0.55;
P < 0.01; Fig. 4). Nevertheless, unstimulated [Ca2], and pH1
were not correlated and each showed no significant correlations
with age or blood pressure in either group when considered
separately.
The thrombin-induced rise in [Ca2]1 as well as in pH, was
also evaluated in the absence of extracellular calcium (Ca20)
by chelation with EGTA 1.2 mmol/liter prior to the addition of
the agonist. Under this condition, the rise in [Ca2]1 represents
mobilization of calcium from intracellular stores. In contrast to
the results obtained in the presence of 1 mmollliter of Ca20, in
the absence of this ion no differences were observed in the
thrombin-induced increase of [Ca2]1 between the two groups
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(EH: 140 18, NT: 121 22, P = 0.27; Table 2; Fig. 2). As
well, the previously observed difference in the thrombin-in-
duced increase in pH1 between both groups was no longer
present in Ca20 free medium (EH: 0.098 0.01, NT: 0.079
0.01, P = 0.25; Table 2).
When Ca21 response to thrombin was abolished with prein-
cubation of platelets with the intracellular calcium chelator
MAPTAM, no significant increase in [Ca2]1 was observed
(data not shown) (Fig. 2). Under this condition, basal unstimu-
lated pH1 was more acidic than in calcium repleted conditions in
both groups (EH: 7.16 0.01 vs. 6.95 0.02, P < 0.001 and
NT: 7.16 0.008 vs. 6.90 0.01, P < 0.001). With thrombin,
no elevation in pH, was observed. On the contrary, a slight
intracellular acidification was observed in both groups (EH:
—0.06 0.008; NT: —0.05 0.008, P = NS; Fig. 2).
Discussion
In the present investigation, we have measured both [Ca2]1
and pH1 in patients with EH and in NT in the resting state and
after stimulation in vitro with human thrombin. It is demon-
strated that stimulation of platelets produced increases in
[Ca2]1 and in pH1, which were significantly greater in patients
0 100 200 300 400 500
[Ca2J, increment, nmol/Iiter
Fig. 4. Relationship between thrombin-induced increments in [Ca'J,
(nmol/liter) and in p1!, (pH units) in (A) controls (r = 0.55; P < 0.01) and
(B) hypertensives (r = 0,65; P < 0.001).
with EH than in NT controls. The agonist-induced increment in
pH1 showed a close relationship with the rise in [Ca2]1 in both
groups of subjects suggesting a central role of Ca21. In this
regard, in calcium-depleted platelets, thrombin was unable to
induce activation of the Na/H exchanger in either group.
Disturbances in Ca21 metabolism have been reported in
experimental and in human hypertension in a variety of cell
models [1, 2]. Unstimulated [Ca2]1 in VSMC has been reported
to be higher in SHR than in normotensive, Wistar-Kyoto rats
(WKY) [27]. Furthermore, arginine-vasopressin-induced in-
creases in rat VSMC [Ca2J1 is higher in SHR as compared to
WKY [28]. In human EH an increased basal platelet [Ca2]1 is
a widely established finding [3—6]. In addition, platelets of
essential hypertensives exhibit a greater degree of agonist-
induced increase in [Ca2]1 [6], reflecting platelet hyperrespon-
siveness. In our hands, the increased response in agonist-
induced rise of [Ca2], in essential hypertensives was due to an
increase in calcium entry into the cell, since no difference in
cellular calcium mobilization (in the absence of extracellular
calcium) was found between EH and NT. This data are in
agreement with 45Ca influx studies performed in rat VSMC [29]
and with studies performed in human platelets [6], suggesting an
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.
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Fig. 3. Relationship between mean arterial pressure and thrombin-
induced increment in (A) [Ca2 '7 (nmol/liter; r = 0.58; P < 0.005) and
(B) in pH1 (pH units; r = 0.59; P < 0.005) in the hypertensive group.
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abnormality in the cell membrane transport of Ca2 in EH. The
parallelism of the alterations in the metabolism of Ca21 be-
tween platelets and VSMC is supported by our finding of a
significant correlation between agonist-induced increase in
[Ca2]1 and MAP in the EH group only in the presence of
extraceilular calcium. In this regard, in experimental hyperten-
sion the calcium antagonist drugs and not other hypotensives
produce greater hypotensive effects than in control animals,
suggesting that enhanced vasoconstriction is maintained by
membrane calcium channel activity [21.
A number of cell types display an increase in pH1 upon
stimulation with agonists and growth factors, and this alkalin-
ization is mediated by stimulation of the amiloride-sensitive
Na/H exchanger [8, 9, 161. Recently, this exchanger has been
cloned [30], and four isoforms have been identified (NHE-l—
NHE-4) [31]. NHE-l is amiloride sensitive and seems to be
expressed in all cell types with basolateral localization in
polarized cells [31]. NHE-2 has reduced susceptibility to inhi-
bition by amiloride and seems to be expressed in polarized
cells, in an apical localization [31]. NHE-3 and NHE-4 are
localized in intestine and stomach, respectively, and their
functional properties are currently being investigated. The
Na/H exchanger activity in response to intracellular acidifi-
cation has been reported to be elevated in circulating cells of
patients with EH both in the absence [11, 18—201 and in the
presence of bicarbonate in the medium [14]. The amiloride
sensitivity of the Na/H exchanger activity determined in
most of these studies argues against the participation of the
NHE-2, and at present, it is not known whether NHE-3 and
NHE-4 are expressed in blood cells. The method employed in
studies evaluating the activity of the Na/H exchanger re-
quires the measurement of the initial rate of pH1 recovery from
an acid load, and in this condition transport activity is assessed
at pH1 values below physiologic resting pH1. We also measured
the kinetics of the Na/H exchanger in response to intracel-
lular acidification in a group of patients and controls. Although
the differences between the small groups of patients and con-
trols were not statistically significant, the tendency displayed
was in agreement with the majority of reports. The activation of
the Na/H exchanger has also been studied in response to
agonists in rat VSMC [32, 33] and has been found to be
significantly increased in the SHR with respect to WKY rats
only in early subcultures of VSMC [34]. To our knowledge at
present, increased agonist-induced rise in pH1 has not been
reported in human hypertension. Our study, performed in the
nominal absence of bicarbonate, demonstrates a significantly
greater agonist-induced intracellular alkalinization, reflecting
activation of the Na/H exchanger, in platelets of patients
with EH as compared to NT controls, despite no differences
found in resting PH1 between both groups. As occurred with
agonist-induced increments in [Ca2]1, agonist-induced in-
creases in platelet pH1 were also significantly correlated with
MAP in the EH group. Both the enhanced rises in platelet
[Ca2], and pH1 seen in patients with EH were observed at low
and high doses of thrombin, suggesting an increased respon-
siveness of platelets from patients with EH.
The concomitant increases in [Ca2]1 and in pH1 upon agonist
activation suggest an interrelationship between these two pa-
rameters. Nevertheless, there is controversy about the relation-
ship between [Ca2]1 elevations and cytoplasmic alkalinization.
Some authors have reported that activation of the Na/H
exchanger after agonist stimuli is a prerequisite for Ca2
mobilization in human platelets [35]. It has been stated that in
EH, the mechanisms involving an increase in intracellular Na
(Na1) are responsible of the elevation of [Ca2]1 through the
membrane Na-Ca2 exchange [36]. The increase in Na1 is
thought to be mediated by a circulating inhibitor of the Nat-
K-ATPase [36, 37]. Otherwise, activation of the amiloride-
sensitive Na/H exchanger also represents a source of Na1
which would be capable of generating increases in [Ca2]1 [35].
Nevertheless, it has been recently demonstrated that activation
of the Na/H exchanger by different stimuli is unable to
produce any measurable effect on [Ca2]1 in rat VSMC [38].
Likewise, the total platelet [Ca2] seems to be independent
from the transmembrane Na gradient [39]. Conversely, sev-
eral reports have pointed out that agonist-induced Ca21 mobi-
lization stimulates the Na/H exchanger in human fibroblasts
[40] and in rat VSMC [41]. Moreover, [Ca2]1 elevation might
be a necessary step for the activation of the exchanger [41—43].
In addition, non-agonist-induced increases in [Ca2]1 are capa-
ble of stimulating the Na/H exchanger in a variety of cell
models [40, 42]. The biochemical mechanisms responsible for
the calcium induced activation of the Na/H exchanger may
involve both protein kinase C-dependent and -independent
pathways [33, 44], the latter possibly mediated by calcium
calmodulin processes [43, 45]. In this respect, it is noteworthy
that protein kinase C activity has been shown to be elevated in
platelets of the SHR [46].
As hypothesized by Aviv [47], it is conceivable that the
association between elevated [Ca2]1 and hyperactivity of the
Na/H exchanger could be a unifying explanation for the
increased vasoactive response, the proliferative process of
vascular muscle cells, and salt sensitivity, which are hallmarks
of EH. The results presented here agree with a Ca2 require-
ment for activation of the Na/H exchanger since in calcium-
depleted platelets, thrombin was unable to activate the ex-
changer. The agonist-induced intracellular alkalinization
showed a close relationship with the agonist-induced increase in
[Ca2]1 in both groups of subjects. In agreement with a hyper-
responsive state, patients with EH showed significantly greater
agonist-induced increases in [Ca2]1 and in pH1 as compared to
the NT subjects. The results of the present work are in
concordance with the hypothesis that a hyperactive Na/H
exchanger in EH could be secondary to an abnormality in the
metabolism of Ca2, [47]. The source of the increased basal and
agonist-induced increase in [Ca2]1 has not been firmly estab-
lished [48], but our data suggest a disturbance in the membrane
transport of Ca2, since both the hyperresponse in stimulated
[Ca2]1 and pH1 in EH were abolished in the absence of
extracellular Ca2t
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